Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cloretazine in Elderly Patients With De Novo Poor Risk AML
NCT00354276Phase 2Unknown
- Sponsor
- Vion Pharmaceuticals
- Start
- May 2006
- Primary completion
- Dec 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of laromustine in acute myeloid leukemia (AML), sponsored by Vion Pharmaceuticals. Primary endpoint: Complete Response Rate. Status: unknown.
02
Drugs
laromustine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00354276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354276.